Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
Status:
Completed
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
This is an open label, Phase III, randomized, controlled, parallel arm multicentre
non-inferiority clinical trial to compare the efficacy and safety of two combination regimens
of Miltefosine and Paromomycin with the standard SSG-PM for the treatment of primary adult
and children VL patients in Eastern Africa.
Phase:
Phase 3
Details
Lead Sponsor:
Drugs for Neglected Diseases
Collaborators:
Kenya Medical Research Institute Makerere University The Institute of Endemic Diseases (IEND), University of Khartoum The Netherlands Cancer Institute University of Gondar